Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Gacyclidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.41 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.39 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.38 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gacyclidine SCHEMBL5398234 | 1.00 | SIGMAR1 (0.56) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL397836 | 0.99 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL7190367 | 0.99 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL3457748 | 0.99 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL4465879 | 0.99 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Hydrochloric Acid SCHEMBL8205944 | 0.83 | MEN1 (0.41) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| SCHEMBL8206550 | 0.82 | MEN1 (0.42) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| SCHEMBL7700857 | 0.80 | PRCP (0.51) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL5402379 | 0.78 | CYP1A2 (0.45) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL14053284 | 0.77 | GRIN1 (0.56) | SIGMAR1PRCPMEN1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| EP-2932971-A1 | KETAMINE FORMULATIONS | Otonomy, Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8771746-B2 | Colloidal suspensions comprising a therapeutic agent and squalene | OTONOMY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120208848-A1 | GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208851-A1 | FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20110136870-A1 | GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2306839-A1 | GACYCLIDINE FORMULATIONS | Neurosystec Corporation (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2307021-A1 | FORMULATIONS | Neurosystec Corporation (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009155421-A1 | GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155401-A1 | FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-2056793-A2 | FREE BASE GACYCLIDINE NANOPARTICLES | Neurosystec Corporation (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2046437-A2 | DEVICES, SYSTEMS AND METHODS FOR OPHTHALMIC DRUG DELIVERY | Neurosystec Corporation (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080152694-A1 | Devices, Systems and Methods for Ophthalmic Drug Delivery | NEUROSYSTEC CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080145439-A1 | NANOPARTICLE DRUG FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008016602-A2 | FREE BASE GACYCLIDINE NANOPARTICLES | NEUROSYSTEC CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008011125-A2 | DEVICES, SYSTEMS AND METHODS FOR OPHTHALMIC DRUG DELIVERY | NEUROSYSTEC CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1861104-A2 | IMPROVED GACYCLIDINE FORMULATIONS | Neurosystec Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060205789-A1 | Gacyclidine formulations | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006096518-A2 | IMPROVED GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | SIGMAR1 3104/4885SLC6A3 2323/4885SLC6A2 1859/4885 |
| US-20110136870-A1 | GACYCLIDINE FORMULATIONS | DCTD, TYMP, TYMS | SIGMAR1 4210/4885SLC6A3 1046/4885SLC6A2 1054/4885 |
| US-20120208848-A1 | GACYCLIDINE FORMULATIONS | DCTD, TYMP, TYMS | SIGMAR1 4210/4885SLC6A3 1046/4885SLC6A2 1054/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | SIGMAR1 3104/4885SLC6A3 2323/4885SLC6A2 1859/4885 |
| US-20060205789-A1 | Gacyclidine formulations | DCTD, TYMP, TYMS | SIGMAR1 4210/4885SLC6A3 1046/4885SLC6A2 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.